Anti-CYBRD1 (HPA014757) antibody for Glioma research - increased expression of CYBRD1
November, 2021 (Department of Clinical Medicine, College of Medicine, Hunan University of Chinese Medicine, China)
Glioma patients with higher CYBRD1 expression predict a poorer prognosis.
The iron reductase, cytochrome B reductase 1 (CYBRD), plays a critical role in carcinogenesis because cancer cells consume more iron than normal cells.
In patients with brain cancers, such as glioma, the increased expression of CYBRD1 is associated with aggravated clinical outcomes and recurrence of gliomas. As a result, glioma patients with higher CYBRD1 expression predict a poorer prognosis.
Our Anti-CYBRD1 (HPA014757) antibody is used in this study (2021) to visualize the CYBRD1 IHC expression in clinical glioma samples of different grades.
Read full article here: https://lnkd.in/dNQTAina
Find out about our Anti-CYBRD1 (HPA014757) antibody on this link.